It has been shown that mice with a targeted mutation in the Ets-1 gene exhibit increased B cell terminal differentiation to IgM-secreting plasma cells. Here, we show that mice, formerly described to lack Ets-1 protein, actually express low levels of an internally deleted Ets-1 protein. 
Introduction
Terminal differentiation of B cells to Ig-secreting plasma cells is a critical step in the immune response. However, excessive B cell activation and differentiation can contribute to autoimmune disease. Thus, the formation of antibody-secreting plasma cells is tightly regulated, in part by the action of particular transcription factors. The transcription factors BCL-6, Pax-5 and Mitf negatively regulate the differentiation of plasma cells from precursors (1) (2) (3) (4) . The transcription factor Ets-1 also appears to play a role in restricting plasmacytic differentiation since Ets-1-deficient mice have an excess of IgM-secreting plasma cells (5) (6) (7) (8) .
Ets transcription factors bind DNA via a winged helix-turnhelix motif known as the Ets domain. In addition, several Ets proteins including Ets-1 contain a conserved region known as the 'Pointed' domain that is involved in protein-protein interactions. In Ets-1, the Pointed domain serves as a docking site for extracellular regulated kinases (Erk) kinases, which subsequently phosphorylate the protein at threonine 38 located upstream of the Pointed domain (9) . The phosphorylation of this conserved residue is correlated with enhanced transcriptional activity of Ets-1 (10) by promoting the recruitment of coactivators such as p300/CREB binding protein (CBP) (11) .
In adult mice, high levels of Ets-1 expression are restricted to lymphoid organs (12, 13) , suggesting that Ets-1 plays an important role in the development or functional differentiation of lymphoid cells. Indeed, the generation of Ets-1-deficient mice by two separate research groups (resulting in two Ets-1-targeted alleles) confirmed an important role for Ets-1 in the differentiation of B cells, T cells, NK cells and NK T cells (5-8, 14, 15) . In one Ets-1 gene-targeted allele, the third and fourth exons of the gene, encoding the Pointed domain, were deleted (6) , whereas in the other allele, the last two exons (exons 8 and 9), encoding the Ets DNA-binding domain, were deleted (5) .
Similar defects in lymphoid cell development were observed in mice with both the Ets-1-targeted alleles. The total number of B cells was within normal limits in Ets-1-deficient mice, but some B cells had a B220 lo IgM + phenotype (5) (6) (7) (8) . Increased numbers of IgM-secreting plasma cells were detected in the peripheral lymphoid organs and serum IgM levels were increased by 5-to 10-fold in Ets-1-deficient mice as compared with control mice (5, 7, 8) . Taken together, these data indicate that Ets-1 is not essential for the development of B cells, but it does play an important role in limiting their terminal differentiation. In this report, we further explore the requirement for Ets-1 in regulating B cell differentiation and functional responses.
Methods

Mice
Mice utilized in this study have been previously described (7, 14) and possess a mixed genetic background (C57BL/6 and 129Sv). Mice were housed in a conventional facility, but maintained in microisolator cages, fed autoclaved food and water and handled only in biosafety cabinets.
Reverse transcriptase-PCR analysis of Ets-1
To clone the mutant version of Ets-1 expressed by Ets-1 genetargeted mice, we designed primers flanking the open reading frame of the murine Ets-1 cDNA (forward primer: CGCC-GGCCCCGTCGACTCCGGGCACCATG, reverse primer: GC-AGGTTCCCGCGGCCGCTTCCTTCTG). These primers contain SalI and NotI restriction sites that allowed us to clone the resulting products in-frame with the hemagglutinin (HA) epitope tag of the vector pCMV-HA (BD Biosciences, San Diego, CA, USA). RNA isolated from purified B cells was reverse transcribed and amplified using Taq polymerase with the primers described above. PCR products were then subcloned into pCMV-HA and sequenced to confirm their identity.
Immunoblotting B cells were purified from the spleens of mice using CD43 microbeads and a VarioMACS magnetic column (Miltenyi Biotec, Auburn, CA, USA) to isolate a negatively selected population. B cell lysates were separated on SDS PAGE gels and transferred to polyvinylidene fluoride (PVDF) membranes. Antibodies used in western blotting were rabbit polyclonal anti-mouse Ets-1 (C-20) from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and mouse anti-b-tubulin (clone KMX-1) from Chemicon (Temecula, CA, USA).
Flow cytometry
Single-cell suspensions were prepared from spleen and lymph nodes of mice. Fluorescently labeled antibodies were obtained from BD Biosciences or Biolegend (San Diego, CA,  USA) and included CD23-PE (B3B4), CD21-FITC (7G6),  CD40-PE (1C10), CD45R/B220-FITC or -PE (RA3-6B2),  CD80-PE (16-10A1), CD86-PE (PO3 or GL-1), CD138-PE  (281-2) , IgM-FITC or -allophycocyanin (11/41), IgD-FITC (11-26c.2a) and MHC class II (I-A and I-E) (M5/114.15.2). Carboxyfluorescein [carboxyfluorescein diacetate succinimidyl ester (CFSE)] was obtained from Molecular Probes (Eugene, OR, USA). Samples were analyzed on a BectonDickinson FACSCalibur and the resulting data were evaluated using FlowJo software. A total of 10 000-20 000 events were obtained in each analysis except for the adoptive transfer experiments in which 100 000 events were obtained. Mean fluorescent intensity (MFI) of staining of each marker was analyzed on B cells or B cell subsets.
Immunofluorescence
Spleens and kidneys of mice were embedded in Tissue-Tek O.C.T. compound (Sakura-Finetec, Torrance, CA, USA), frozen in liquid nitrogen and sectioned at 6 lm. After blocking, tissue sections were labeled with specific antibodies for 1 h at room temperature. Kidney sections were incubated with monoclonal anti-mouse IgM-FITC (11/41, BD Biosciences), polyclonal anti-mouse IgG-FITC (Jackson ImmunoResearch, West Grove, PA, USA) or polyclonal anti-mouse complement C3-FITC (MP Biomedical, Irvine, CA, USA). Spleen sections were incubated with a combination of biotinylated mouse antimouse CD22 (Cy34, BD Biosciences) and rat anti-mouse metallophilic macrophage mAb (Moma-1; Serotec, Raleigh, NC, USA). After washing, the spleen sections were incubated with secondary reagents: streptavidin-conjugated Alexa-Fluor 488-and Alexa-Fluor 568-labeled goat anti-rat secondary antibody (Molecular Probes). Stained slides were mounted using VectaShield (Vector Labs, Burlingame, CA, USA) and photographed with a Nikon FXA fluorescence microscope.
Adoptive transfer
B cells were purified from the spleens of donor mice (as indicated in the figure legends) using magnetic depletion of CD43 + non-B cells. For some experiments, expression of activation markers (CD23, CD80, CD86 and MHC II) was assessed on bulk B cells prior to adoptive transfer. Purified B cells were labeled with 1 lM CFSE for 3 min, washed and then injected retro-orbitally into anesthetized C57BL/6 3 129Sv hybrid wild-type or Ets-1 p/p host mice. Three to five days posttransfer, spleens of host mice were harvested and the phenotype of transferred B cells was analyzed by flow cytometry. Data were analyzed by gating on the CFSE + population in the spleen and assessing the expression of surface markers. MFI of each marker on the CFSE + population was determined.
ELISA
Serum was harvested from mice via eye bleed or cardiac puncture and stored at ÿ20°C until analyzed. ELISA capturing agents were coated onto NUNC-Immuno Maxi-Sorp 96-well plates at 10 lg ml ÿ1 . The capturing agents used were trinitrophenol (TNP) (Sigma Chemical, St Louis, MO, USA), double-stranded sheared salmon sperm DNA (Eppendorf Scientific, Westbury, NY, USA), a natural mixture of histones H1, H2A, H2B, H3 and H4 from calf thymus (Roche Applied Sciences, Indianapolis, IN, USA), bovine heart cardiolipin (Sigma Chemical), bovine brain MBP (Sigma Chemical) and a mixture of mouse IgG antibodies (SouthernBiotech, Birmingham, AL, USA). Mouse serum was diluted 1: 1000 in PBS plus 4% BSA and incubated on the coated ELISA plates. After washing, the plates were incubated with biotinconjugated anti-mouse kappa and lambda light chain antibodies (for detection of antibodies against DNA, histones, cardiolipin and MBP) or with biotin-conjugated anti-mouse IgM (for detection of antibodies against mouse IgG or TNP). Plates were subsequently incubated with avidin-HRP complex (eBiosciences, San Diego, CA, USA) and developed using 3,39,5,59-tetramethylbenzidine substrate solution (eBiosciences). Absorbances were read at 450 nm on a Bio-Rad ELISA microplate reader.
B cell stimulation and ELISPOT
B cells were purified from the spleens of mice as described above. Purified B cells were cultured at 37°C with 5% CO 2 in RPMI-1640 medium supplemented with 10% FCS, penicillin/ streptomycin, glutamine and 50 lM b-mercaptoethanol. Cells were either unstimulated or stimulated for 72 h with 10 lg ml ÿ1 goat F(ab9) 2 anti-mouse IgM antibody l chain specific (Jackson ImmunoResearch), 10 lg ml ÿ1 bacterial LPS (Sigma Chemical) or 5 lg ml ÿ1 phosphorothioate oligodeoxynucleotides (ODN) [the previously described (16) stimulatory ODN 1826 (59 TCCATGACGTTCCTGACGTT 39) and control ODN 2138 (59 TCCATGAGCTTCCTGAGCTT 39), a kind gift of Arthur Krieg and Coley Pharmaceuticals]. In some experiments, 0.1 lM chloroquine diphosphate (Sigma Chemicals) was added to cells stimulated with ODN 1826. For ELISPOT analysis, Millipore MultiScreen 96-well plates with Immobilon-P membrane were coated with 10 lg ml ÿ1 of polyclonal goat anti-mouse Ig (SouthernBiotech). B cells, stimulated as described above, were plated at 250, 1000, 5000 and 20 000 cells per well and incubated overnight at 37°C. IgM-secreting plasma cells were detected using a biotin-conjugated rat antimouse IgM (R6-60.2; BD Biosciences) detection antibody followed by avidin-HRP complex (VectaStain ABC Peroxidase Kit; Vector Labs) and 3-amino-9-ethyl carbazole (Sigma Chemical). ELISPOT plates were counted with an automated reader (Zellnet Consulting, Fort Lee, NJ, USA).
Statistics
Data are represented as mean 6 SEM. Statistical significance of differences in Tables and Figures was assessed using a paired two-tailed Student's t-test.
Methods for Online Supplementary Data
Differentiation of LPS-and cytosine-phosphate-guanine DNA sequence (CpG)-stimulated B cells was assessed by immunofluorescent staining for cytoplasmic IgM. Cells stimulated for 72 h were allowed to settle onto polylysine coated cover slips. Attached cells were then fixed in 100% methanol and stained with FITC-coupled anti-mouse IgM antibody. Stained slides were mounted using VectaShield and photographed with a Nikon FXA fluorescence microscope.
HeLa cervical carcinoma cells were grown in DMEM supplemented with 10% FCS, glutamine and penicillin/streptomycin. The day prior to transfection, 150 000 cells were plated in each well of a 6-well plate. Cells were transfected the next day with Fugene-6 reagent (Roche Applied Sciences) according to the directions supplied by the manufacturer. A total of 200 ng of a plasmid driving expression of HA-tagged mouse Ets-1 (pCMV-HA-Ets1) was co-transfected with 500 ng of Ets-dependent reporter (E7433)-TK-Luc, containing three copies of an Ets-binding site cloned upstream of the TK minimal promoter and a firefly luciferase reporter gene (a kind gift of Satrajit Sinha, SUNY at Buffalo, Buffalo, NY, USA). Cells were co-transfected with varying amounts (0, 10, 50, 200, 800 or 2000 ng) of a plasmid-driving expression of HA-tagged mutant Ets-1 cloned from Ets-1 p/p mice (pCMV-HA-Ets1DP). Cells were also co-transfected with 200 ng of an internal control plasmid pEF-RLuc, containing the constitutively expressed EF1a promoter driving expression of Renilla luciferase (a kind gift of Xin Lin, Anderson Cancer Center, University of Texas, Houston, TX, USA). Forty-eight hours post-transfection, cells were harvested and lysed. Firefly and Renilla luciferase values were measured using the Dual-luciferase kit (Promega) and expressed as ratios of firefly luciferase to Renilla luciferase.
Results
Ets-1-deficient mice express a mutant version of Ets-1 lacking the Pointed domain
Generation of the Ets-1 gene-targeted mutant mice used in this study has previously been described (6, 7). The gene-targeting event that gave rise to the Ets-1 knockout allele results in deletion of exon 3 and a portion of exon 4, which encode the Pointed domain of Ets-1. Analysis of the genomic organization of Ets-1 revealed that exons 2 and 5 were in the same reading frame, suggesting that splicing around the inserted neomycin resistance gene could potentially lead to production of a transcript encoding an in-frame fusion of Ets-1 lacking the Pointed domain. To test this possibility, we performed reverse transcriptase (RT)-PCR analysis using RNA derived from purified B cells and primers flanking the open reading frame of the Ets-1 gene. As shown in Fig. 1(A) , wild-type B cells produce an RT-PCR product of the expected size (1.3 kb) whereas Ets-1 ÿ/ÿ B cells produce a smaller transcript of~1.0 kb and Ets-1 +/ÿ B cells produce both transcripts. We cloned and sequenced the 1.0-kb PCR fragment derived from Ets-1 gene-targeted B cells and showed that it indeed encoded an mRNA species lacking exons 3 and 4 and in which exon 2 was fused in-frame to exon 5. This transcript presumably arises due to alternate splicing around the neomycin gene.
To determine whether the mutant mRNA species gives rise to a protein product, we performed western blot analysis using lysates prepared from Ets-1 +/+ , Ets-1 +/ÿ and Ets-1 ÿ/ÿ thymocytes. In lysates from wild-type mice, two major isoforms of Ets-1 (p54 Ets-1 and p42 Ets-1) are detected, which arise via alternate splicing of exon 7 (17, 18) . As shown in Fig. 1 Figure 1 (C) shows the predicted domain structure of the mutant protein, which retains the Erk kinase phosphorylation site, acidic transactivation domain, autoinhibitory domains and Ets DNA-binding domain.
Mice expressing the hypomorphic allele of Ets-1 exhibit striking lymphoid abnormalities as described previously (6, 7, 14) and in the data presented below. Since expression of the deleted form of the Ets-1 protein is very low as compared with expression of the wild-type protein, we propose that the Ets-1 p/p phenotype is likely to be the result of near total loss of Ets-1 activity. However, we cannot exclude the possibility that expression of a mutant form of Ets-1 lacking the Pointed domain may also have effects on B cell differentiation.
B cell development is altered in Ets-1 p/p mice
Loss of Ets-1 activity has previously been shown to result in increased numbers of B220 lo IgM + B cells in the lymphoid organs (5-8), which we have confirmed ( Fig. 2A-C) . In order to distinguish immature, transitional and mature B cell populations in the peripheral lymphoid tissues, we stained spleen cells with antibodies specific for IgM and IgD. 
Ets-1 p/p B cells express increased levels of activation markers
CD23 is known to be up-regulated on B cells by CD40 ligation or IL-4 stimulation (19, 20) . Thus, increased expression of CD23 on B cells from Ets-1 p/p mice may reflect an activated state. To explore this possibility in more detail, we stained spleen and lymph node suspensions with antibodies specific for surface markers that are up-regulated in activated B cells (MHC II, CD40, CD80 and CD86). Tables 1 and 2 ). Few or none of the CFSE + cells stained with the plasma cell-specific marker CD138 (data not shown), suggesting that these cells had not differentiated to plasma cells. Hence, the activated phenotype and increased terminal differentiation of Ets-1 p/p B cells are reversed when the cells are transferred to wild-type hosts, indicating that factors in the wild-type environment function to limit the activity of Ets-1-deficient B cells.
To determine whether wild-type B cells could respond to the factors in the Ets-1 p/p environment that induce B cell activation, we reversed the transfer experiments and introduced purified CFSE-labeled wild-type B cells into Ets-1 p/p hosts. After 3 days post-transfer, we analyzed the expression of activation markers on CFSE + wild-type B cells. As can be seen in Table 3 (Fig. 3A) . These IgM-secreting cells do not represent contamination of the purified B cell population with plasma cells because their development could be strongly suppressed by stimulation with anti-IgM BCR cross-linking antibody. Thus, Ets-1 p/p B cells have an intrinsic propensity to differentiate to IgM-secreting cells, which can be suppressed by BCR ligation. (Fig. 3A and B) . Even a control ODN (ODN 2138) containing GpC motifs, rather than CpG motifs, was capable of inducing some differentiation of Ets-1 p/p B cells (Fig. 3B ). This result is in agreement with previous observations that the control ODN utilized in our studies (ODN 2138) induces weak TLR9-dependent signaling leading to T h 2-biased in vivo responses (16) .
To further explore the responses of mutant B cells to TLR9 activation, we incubated purified B cells with CpG ODN in the presence of a low concentration (0.1 lM) of the endosomal maturation inhibitor chloroquine, which blocks p38 kinase and AP-1 activation induced by CpG ODN (21, 22) . We used a low concentration of chloroquine in our studies because higher levels led to significant toxicity over the 72-h incubation period. These experiments confirmed that Ets-1 p/p B cells are hyperresponsive to CpG stimulation and that this response can be partially inhibited by low levels of chloroquine (Fig. 3B) . Note that we detected lower numbers of IgM-secreting cells in these experiments as compared with those detected in the experiments shown in Fig. 3(A) . This difference can be explained by the fact that the B cells were incubated for a shorter time on the ELISPOT plates (6 h for the experiments shown in Fig. 3B versus 18 h in the experiments shown in Fig. 3A) . However, the overall trend of hyperresponsiveness of Ets-1 p/p B cells to CpG ODN stimulation is evident in both sets of experiments. To verify that each population of B cells responded to CpG ODN, we measured B cell proliferation (indicated by the dilution of CFSE staining) and activation (indicated by the up-regulation of CD86) after 72 h of incubation with ODN 1826. As shown in Fig. 3(C) , B cells of each genotype underwent similar levels of proliferation and up-regulated CD86 to similar extents. Differentiation of B cells in response to LPS and CpG ODN was further confirmed using immunofluorescent staining of cytoplasmic IgM (Supplementary Figure 2 , available at International Immunology Online).
In contrast to the hyperresponsiveness of Ets-1 p/p B cells to CpG ODN, there was no enhanced differentiation response to BCR cross-linking antibody or to bacterial LPS (a TLR4 agonist) (Fig. 3A) . Indeed, Fig. 4(A) , Ets-1 p/p mice produce low, but detectable, levels of antibody specific for a foreign antigen. This presumably reflects low levels of nonantigen-specific differentiation of Ets-1 p/p B cells to Igsecreting cells (perhaps driven by responses to CpG). In contrast, there are greatly increased levels of autoreactive antibodies specific for each potential self-antigen tested (double-stranded DNA, histones, cardiolipin, MBP and IgG) in the serum of Ets-1 p/p mice. Analysis of the isotypes of the auto-antibodies indicated that both IgM and IgG auto-antibodies are produced (data not shown). These data suggest that auto-antibody production is antigen driven and likely involves interaction of B cells with autoreactive T cells.
To determine whether the hyperactive B cells and autoantibodies found in Ets-1 p/p mice lead to organ pathology, we examined sections of various organs for evidence of inflammation or other pathological changes. The spleen and lymph nodes of Ets-1 p/p mice were frequently enlarged and contained foci of plasma cells. In addition, there was often extramedullary hematopoiesis in the spleen. The lungs of nearly all Ets-1 p/p mice (five of six) examined contained mild inflammatory infiltrates into the perivascular, peribronchial and sub-pleural regions (Fig. 4B) . Such infiltrates could also be detected in the majority of Ets-1 +/p mice (four of five), but not Ets-1 +/+ mice (zero of four). Lung infiltration tended to be less prominent in heterozygous mutant mice than homozygous mutant mice. Mild inflammatory infiltrates were also detected in the livers of most Ets-1 p/p mice (4 of 6), but only one of five Ets-1 +/p mice and zero of four Ets-1 +/+ mice (Fig. 4B) . These infiltrates were mainly detected in the region surrounding the gall bladder and the common bile duct. Although we cannot rule out infection with pathogenic organisms, we hypothesize that the infiltrates in the lungs and livers of Ets-1 p/p mice represent an autoimmune attack by self-reactive lymphocytes.
Kidneys from Ets-1 p/p mice generally exhibited mild to moderate thickening of the glomerular basement membrane occasionally accompanied by infiltrating lymphocytes. Kidney sections from 6-to 12-week-old Ets-1 p/p mice exhibited extensive glomerular staining with anti-mouse IgM, anti-mouse IgG and anti-mouse complement C3 antibodies, demonstrating the deposition of immune complexes in this tissue (Fig. 4C) .
Ets-1
+/p kidneys also exhibited weak staining with anti-IgM, CFSE-labeled C57BL/6 wild-type B cells were transferred to unirradiated Ets-1 p/p hosts and analyzed by flow cytometry after 3 days. MFI and SEM are shown for the expression of MHC II, CD23, CD80 and CD86 on total B cells prior to transfer and on the CFSE + population after transfer. Asterisks indicate P-values that are statistically significant (P < 0.05). anti-IgG and anti-complement C3 antibodies, whereas kidneys from wild-type mice did not exhibit specific staining (Fig. 4C) . Despite the extensive immune complexes, only rare and mild inflammatory infiltrates were detected in the kidneys of mutant mice. Moreover, measurements of urine protein levels in mice up to the age of 29 weeks failed to show increased urinary protein concentrations in mutant mice. Together, our results indicate that Ets-1 p/p mice develop a systemic autoimmune disease affecting multiple organs.
Discussion
The mice used in our study, previously described as being completely deficient in Ets-1 protein, actually expressed low levels of a hypomorphic allele of Ets-1 lacking the Pointed domain. The Pointed domain of Ets-1 interacts with Erk kinases, which subsequently phosphorylate Ets-1 on a threonine residue (T38) located upstream of the Pointed domain (9, 10, 23) . Phosphorylation of this residue results in recruitment of the co-activator proteins CBP and p300 to Ets-1, leading to an enhanced transcriptional activation function (11) . The Ets-1 p mutant protein could theoretically function as a dominant negative transcription factor by binding to DNA but failing to activate transcription efficiently. Indeed, in transient transfection assays, the Ets-1 p protein was capable of dominantly inhibiting activation of a reporter gene by wild-type Ets-1 (Supplementary Figure 3 , available at International Immunology Online). However, such inhibition required very high concentrations of the mutant protein. Since we have shown by western blotting that in Ets-1 p/p mice the Pointed domain-deficient mutant protein is expressed at very low levels, it is unlikely that it serves as a dominant negative in vivo. Moreover, the alterations in lymphocyte development found in Ets-1 p/p mice are very similar to those found in a separate line of Ets-1 gene-targeted mice in which exons 8 and 9 (encoding the Ets DNA-binding domain) were deleted (5, 8, 15) . Hence, we propose that the phenotype of these mice results from the near total absence of Ets-1 activity rather than from expression of a mutant version of Ets-1.
Loss of Ets-1 leads to alterations in the development of B lymphocytes that share some similarities with those found in other strains of gene-targeted mutant mice. In particular, mice deficient in the tyrosine kinase Lyn have large numbers of IgM-secreting plasma cells in their peripheral lymphoid organs and produce auto-antibodies (24, 25) . Ets-1 p/p B cells express normal levels of Lyn (by western analysis, unpublished results), suggesting that the defect in these mice is not attributable to reduced expression of Lyn. Ets-1 p/p mice also exhibit a number of phenotypic similarities to mice lacking the transcription factor Aiolos. In Aiolos ÿ/ÿ mice, follicular B cells exhibit an activated cell-surface phenotype and secrete autoantibodies, leading to the deposition of immune complexes in the kidney (26, 27) . Aiolos ÿ/ÿ mice, like Ets-1 p/p mice, lack marginal zone B cells, although they differ from Ets-1 p/p mice in that they also lack B-1 B cells (26) . Ets-1 p/p mice also differ from Aiolos ÿ/ÿ mice in that they do not appear to form spontaneous germinal centers and lack elevated serum titers of IgG or IgE.
Ets-1 p/p mice have normal numbers of B-1a B cells in the peritoneal cavity and B-2 B cells in the lymphoid organs, but lack marginal zone B cells in the spleen. This is in contrast to a report by Eyquem et al. (8) that mice harboring an independently generated Ets-1 mutation lack both B-1a B cells and marginal zone B cells. The explanation for this difference in phenotype is currently unclear. However, B-1a B cell development may require only residual levels of Ets-1 activity (present in Ets-1 p/p mice), but may be incompatible with a complete absence of Ets-1 activity (reported for mice harboring the other Ets-1-targeted allele). Alternatively, the difference may be explained by genetic background effects (Ets-1 p/p mice are on a mixed 129Sv 3 C57BL/6 background, whereas the mice of Eyquem et al. are on a C57BL/6 background). Our data demonstrate that Ets-1-deficient B cells also have cell-intrinsic changes as they exhibited increased rates of differentiation to IgM-secreting plasma cells when stimulated in vitro via TLR9. This observation suggests that Ets-1 functions to limit TLR9 signaling pathways and thereby limits B cell terminal differentiation. To our knowledge, this represents the first description of a transcription factor that acts to inhibit TLR9 signaling pathways and it will be of considerable interest to identify Ets-1 target genes that regulate the TLR9 signaling pathway in future experiments. Several proteins have already been described that limit signaling through TLR pathways including interleukin-1 receptor associated kinase (IRAK-2), IRAK-M, Triad3A and single Ig IL-1R-related molecule (SIGIRR) (39) . Further studies will be required to determine if one or more of the genes encoding these proteins is misexpressed in Ets-1 p/p B cells. The regulation of the TLR9 response by Ets-1 is an interesting observation because TLR9-mediated signals have been implicated in the development or progression of a number of autoimmune diseases using animal models (40) (41) (42) (43) (44) (45) . Recent evidence suggests that TLR9-mediated activation of immune cells may also be relevant to human autoimmune diseases (46) . Mechanisms by which CpG-containing DNA complexes can stimulate autoreactive B cells have been studied using anti-IgG (rheumatoid factor) B cells and anti-DNA B cells (47, 48) . In these autoreactive cells, binding of the BCR to DNA molecules or to immune complexes containing DNA leads to internalization of the DNA, stimulation of TLR9-dependent signaling pathways and activation of B cell proliferation (47, 48) . Thus, CpG motifs represent a potential danger to the organism by promoting the activation of autoreactive B cells. The transcription factor Ets-1, by restraining B cell differentiation in response to CpG motifs, may play an important role in limiting TLR9-mediated promotion of autoimmune diseases.
In contrast to the excessive differentiation induced by TLR9 activation, purified Ets-1-deficient B cells did not exhibit enhanced differentiation in response to LPS. Indeed, the numbers of IgM-secreting plasma cells detected in LPSstimulated Ets-1 p/p cultures were reduced as compared with those found in control cultures. Although the decreased response to LPS may reflect inherent alterations in this pathway, it is also possible that the decreased responses to LPS activation reflect the reduced numbers of marginal zone B cells in Ets-1 p/p mice since marginal zone B cells are reported to be much more responsive to LPS-induced differentiation than are follicular B cells (28, 29) .
The increased B cell activity in Ets-1 p/p mice is correlated with the development of autoimmune disease. Mice with autoimmune syndromes often exhibit the deposition of immune complexes in their kidneys (24, (49) (50) (51) (52) (53) (54) . Such complexes can function to recruit other inflammatory cells and to activate the complement, leading to severe kidney damage and proteinuria. Although Ets-1 p/p mice have significant immune complexes in their kidneys, only mild glomerulonephritis was present and increased urinary protein levels were not detected in mice (up to~6 months of age). The fairly mild inflammation found in the kidney is somewhat counter-intuitive, given the high levels of auto-antibodies in the serum and the extensive immune complex deposition. However, it should be noted that Ets-1 p/p mice have alterations in the T cell, NK cell and NK T cell compartments (6, 7, 14) , which likely influence inflammatory cell recruitment and activation. Our studies have shown that Ets-1-deficient B cells have an intrinsic propensity to undergo differentiation to plasma cells as demonstrated by their increased in vitro differentiation in response to CpG ODN. These results support the idea that Ets-1 is a critical negative regulator of B cell terminal differentiation induced by TLR9. As such, Ets-1 may be essential for limiting B cell responses to T cell-independent signaling pathways in vivo and for limiting the activation of autoreactive B cells exposed to TLR9 ligands.
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Supplementary data are available at International Immunology Online.
